149 related articles for article (PubMed ID: 12037748)
21. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT.
Hishiki T; Matsunaga T; Sasaki F; Yano M; Ida K; Horie H; Kondo S; Watanabe K; Oue T; Tajiri T; Kamimatsuse A; Ohnuma N; Hiyama E
Pediatr Surg Int; 2011 Jan; 27(1):1-8. PubMed ID: 20922397
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.
Perilongo G; Maibach R; Shafford E; Brugieres L; Brock P; Morland B; de Camargo B; Zsiros J; Roebuck D; Zimmermann A; Aronson D; Childs M; Widing E; Laithier V; Plaschkes J; Pritchard J; Scopinaro M; MacKinlay G; Czauderna P
N Engl J Med; 2009 Oct; 361(17):1662-70. PubMed ID: 19846851
[TBL] [Abstract][Full Text] [Related]
23. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2.
Perilongo G; Shafford E; Maibach R; Aronson D; Brugières L; Brock P; Childs M; Czauderna P; MacKinlay G; Otte JB; Pritchard J; Rondelli R; Scopinaro M; Staalman C; Plaschkes J;
Eur J Cancer; 2004 Feb; 40(3):411-21. PubMed ID: 14746860
[TBL] [Abstract][Full Text] [Related]
24. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
25. Vincristine/irinotecan/temsirolimus upfront window treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 Study Committee.
Thompson PA; Malogolowkin MH; Furman WL; Piao J; Krailo MD; Chung N; Brock L; Towbin AJ; McCarville EB; Finegold MJ; Ranganathan S; Dunn SP; Langham MR; McGahren ED; Tiao GM; Weldon CB; O'Neill AF; Rodriguez-Galindo C; Meyers RL; Katzenstein HM
Pediatr Blood Cancer; 2023 Jul; 70(7):e30365. PubMed ID: 37073741
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
[TBL] [Abstract][Full Text] [Related]
27. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.
Zsiros J; Brugieres L; Brock P; Roebuck D; Maibach R; Zimmermann A; Childs M; Pariente D; Laithier V; Otte JB; Branchereau S; Aronson D; Rangaswami A; Ronghe M; Casanova M; Sullivan M; Morland B; Czauderna P; Perilongo G;
Lancet Oncol; 2013 Aug; 14(9):834-42. PubMed ID: 23831416
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.
Zsíros J; Maibach R; Shafford E; Brugieres L; Brock P; Czauderna P; Roebuck D; Childs M; Zimmermann A; Laithier V; Otte JB; de Camargo B; MacKinlay G; Scopinaro M; Aronson D; Plaschkes J; Perilongo G
J Clin Oncol; 2010 May; 28(15):2584-90. PubMed ID: 20406943
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children's Hepatic Tumors International Collaboration (CHIC).
Trobaugh-Lotrario AD; Maibach R; Aronson DC; Rangaswami A; Häberle B; O'Neill AF; Schmid I; Ansari M; Hishiki T; Ranganathan S; Alaggio R; de Krijger RR; Tanaka Y; Cho SJ; Vokuhl C; Maxwell R; Krailo M; Hiyama E; Czauderna P; Finegold M; Feusner JH; Malogolowkin MH; Meyers RL; Lopez-Terrada D
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672416
[TBL] [Abstract][Full Text] [Related]
30. Surgical management in hepatoblastoma: points to take.
Murawski M; Weeda VB; Czauderna P
Pediatr Surg Int; 2023 Jan; 39(1):81. PubMed ID: 36631526
[TBL] [Abstract][Full Text] [Related]
31. Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids.
Song H; Bucher S; Rosenberg K; Tsui M; Burhan D; Hoffman D; Cho SJ; Rangaswami A; Breese M; Leung S; Ventura MVP; Sweet-Cordero EA; Huang FW; Nijagal A; Wang B
Nat Commun; 2022 Aug; 13(1):4878. PubMed ID: 36008377
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: Report from Children's Oncology Group Trial, AHEP0731.
Vasudevan SA; Meyers RL; Finegold MJ; López-Terrada D; Ranganathan S; Dunn SP; Langham MR; McGahren ED; Tiao GM; Weldon CB; Malogolowkin MH; Krailo MD; Piao J; Randazzo J; Towbin AJ; BethMcCarville M; O'Neill AF; Furman WL; Rodriguez-Galindo C; Katzenstein HM
J Pediatr Surg; 2022 Oct; 57(10):251-256. PubMed ID: 35810020
[TBL] [Abstract][Full Text] [Related]
33. Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study.
Short SS; Kastenberg ZJ; Wei G; Bondoc A; Dasgupta R; Tiao GM; Watters E; Heaton TE; Lotakis D; La Quaglia MP; Murphy AJ; Davidoff AM; Mansfield SA; Langham MR; Lautz TB; Superina RA; Ott KC; Malek MM; Morgan KM; Kim ES; Zamora A; Lascano D; Roach J; Murphy JT; Rothstein DH; Vasudevan SA; Whitlock R; Lal DR; Hallis B; Bütter A; Baertschiger RM; Lapidus-Krol E; Putra J; Tracy ER; Aldrink JH; Apfeld J; Le HD; Park KY; Rich BS; Glick RD; Fialkowski EA; Utria AF; Meyers RL; Riehle KJ
Cancer; 2022 Jul; 128(14):2786-2795. PubMed ID: 35561331
[TBL] [Abstract][Full Text] [Related]
34. Current Approaches in Hepatoblastoma-New Biological Insights to Inform Therapy.
Wu PV; Rangaswami A
Curr Oncol Rep; 2022 Sep; 24(9):1209-1218. PubMed ID: 35438389
[TBL] [Abstract][Full Text] [Related]
35. Predictors of survival following liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma: Experience from the Society of Pediatric Liver Transplantation (SPLIT).
Boster JM; Superina R; Mazariegos GV; Tiao GM; Roach JP; Lovell MA; Greffe BS; Yanni G; Leung DH; Elisofon SA; McDiarmid SV; Gupta NA; Lobritto SJ; Lemoine C; Stoll JM; Vitola BE; Daniel JF; Sayed BA; Desai DM; Martin AE; Amin A; Anand R; Anderson SG; Sundaram SS
Am J Transplant; 2022 May; 22(5):1396-1408. PubMed ID: 34990053
[TBL] [Abstract][Full Text] [Related]
36. Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study.
Katzenstein HM; Malogolowkin MH; Krailo MD; Piao J; Towbin AJ; McCarville MB; Tiao GM; Dunn SP; Langham MR; McGahren ED; Finegold MJ; Ranganathan S; Weldon CB; Thompson PA; Trobaugh-Lotrario AD; O'Neill AF; Furman WL; Chung N; Randazzo J; Rodriguez-Galindo C; Meyers RL
Cancer; 2022 Mar; 128(5):1057-1065. PubMed ID: 34762296
[TBL] [Abstract][Full Text] [Related]
37. Genetic and epigenetic basis of hepatoblastoma diversity.
Nagae G; Yamamoto S; Fujita M; Fujita T; Nonaka A; Umeda T; Fukuda S; Tatsuno K; Maejima K; Hayashi A; Kurihara S; Kojima M; Hishiki T; Watanabe K; Ida K; Yano M; Hiyama Y; Tanaka Y; Inoue T; Ueda H; Nakagawa H; Aburatani H; Hiyama E
Nat Commun; 2021 Sep; 12(1):5423. PubMed ID: 34538872
[TBL] [Abstract][Full Text] [Related]
38. Recent improvement in survival outcomes and reappraisal of prognostic factors in hepatoblastoma.
Koh KN; Namgoong JM; Yoon HM; Cho YA; Choi SH; Shin J; Kang SH; Suh JK; Kim H; Oh SH; Kim KM; Kim DY; Im HJ
Cancer Med; 2021 May; 10(10):3261-3273. PubMed ID: 33939313
[TBL] [Abstract][Full Text] [Related]
39. Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer.
Hirsch TZ; Pilet J; Morcrette G; Roehrig A; Monteiro BJE; Molina L; Bayard Q; Trépo E; Meunier L; Caruso S; Renault V; Deleuze JF; Fresneau B; Chardot C; Gonzales E; Jacquemin E; Guerin F; Fabre M; Aerts I; Taque S; Laithier V; Branchereau S; Guettier C; Brugières L; Rebouissou S; Letouzé E; Zucman-Rossi J
Cancer Discov; 2021 Oct; 11(10):2524-2543. PubMed ID: 33893148
[TBL] [Abstract][Full Text] [Related]
40. Management of hepatoblastoma in the United States: Can we do better?
Ziogas IA; Benedetti DJ; Wu WK; Matsuoka LK; Izzy M; Rauf MA; Pai AK; Bailey CE; Alexopoulos SP
Surgery; 2021 Aug; 170(2):579-586. PubMed ID: 33526266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
